Angle-Closure Glaucoma Risk and Your Genetics

Written by Scott Peeples, BS Biomedical Sciences · ExomeDNA Founder Reviewed by ExomeDNA Editorial Process · [/methodology/editorial-process] Last reviewed: May 2026

This page is general information only. For health decisions, consult a clinician.

Angle-closure glaucoma is a form of glaucoma in which the eye's internal drainage angle — the channel between the iris and cornea through which fluid exits — becomes physically blocked or narrowed, raising pressure inside the eye. Heritability studies place genetic contribution to glaucoma subtypes in the moderate-to-substantial range, and large multi-ancestry genome-wide studies have identified specific loci near GLIS3, HERC2, KCNQ5, and PCMTD1 as variants associated with angle-closure risk.^[1] Below: how the drainage angle works, the genes most consistently implicated, and what current research suggests about monitoring and prevention.

What is angle-closure glaucoma?

Angle-closure glaucoma (ACG) is a mechanically distinct subtype of glaucoma caused by the iris physically approaching or contacting the trabecular meshwork — the spongy tissue at the iridocorneal angle that drains aqueous humor out of the eye. When that drainage pathway is blocked, intraocular pressure (IOP) rises, and sustained elevated pressure damages the optic nerve over time.

ACG differs importantly from primary open-angle glaucoma (POAG), the more common form in Western populations. In POAG, the drainage angle remains anatomically open but the trabecular meshwork functions poorly. In ACG, the angle itself is obstructed by direct iris contact. The distinction matters because the clinical presentations, risk populations, and partly the underlying genetic architecture differ between the two forms.

ACG can present in two main ways. An acute angle-closure crisis is a medical emergency: sudden, severe eye pain, blurred vision, seeing halos around lights, headache, and sometimes nausea. This occurs when the drainage angle closes rapidly and pressure spikes. Chronic angle-closure progresses silently over months to years, with gradual optic nerve damage and peripheral vision loss before symptoms appear — similar in silence to open-angle glaucoma, but caused by anatomical narrowing rather than trabecular dysfunction.

Worldwide, ACG accounts for a disproportionate share of glaucoma-related blindness relative to its prevalence, in part because the acute form can cause rapid irreversible damage if untreated, and the chronic form often goes undetected until late. ACG is more prevalent in East Asian populations and in people with shorter axial eye length (more farsighted, or hyperopic, eyes tend to have shallower anterior chambers with narrower angles).

The genetics behind angle-closure glaucoma

The anterior chamber of the eye — the fluid-filled space between the cornea and lens — has a depth and angle that is substantially heritable. Shallower anterior chambers are the primary anatomical predispositor to angle closure, and genes that shape anterior segment development during embryogenesis directly influence this geometry.

A large multi-ancestry genome-wide association study of primary angle-closure glaucoma identified several loci with consistent signals across diverse ancestry groups.^[1] The genes at or near these signals include GLIS3, HERC2, KCNQ5, and PCMTD1 — each contributing to angle-closure biology through distinct mechanisms.

GLIS3 encodes Gli-similar zinc finger protein 3, a nuclear transcription factor expressed during the development of multiple organ systems including the retina and ciliary body. GLIS3 carries five C2H2-type zinc finger domains and regulates the expression of downstream genes critical for anterior segment formation. During eye development, GLIS3 is active in the ciliary body — the ring of tissue behind the iris that produces aqueous humor. Genetic variation affecting GLIS3 expression may alter how the anterior segment is shaped, influencing the final depth of the anterior chamber and the width of the drainage angle. People who inherit variants in this region may develop eyes with anatomically narrower angles, increasing the lifetime probability of angle-closure events.

HERC2 encodes a large E3 ubiquitin ligase on chromosome 15q13, immediately adjacent to the OCA2 pigmentation gene. HERC2 is a master regulator of OCA2 expression, and variants here are among the strongest genetic determinants of human iris, skin, and hair color. The pigmentation connection to ACG is biologically plausible: iris anatomy — including thickness and the degree to which the iris bows anteriorly — varies across eye color backgrounds and ancestry groups. The HERC2/OCA2 locus may influence anterior chamber geometry through developmental effects on iris and ciliary body morphology, offering a mechanistic link from pigmentation genetics to angle-closure susceptibility.

KCNQ5 encodes a voltage-gated potassium channel (Kv7.5) expressed in neural tissue and the eye's ciliary epithelium, where potassium channels participate in active ion transport that drives aqueous humor secretion. Potassium channel activity also influences trabecular meshwork smooth muscle tone, modulating outflow resistance. KCNQ5 variants may alter aqueous dynamics affecting the pressure balance that keeps the drainage angle open.

PCMTD1 encodes a predicted protein repair enzyme (protein-L-isoaspartate O-methyltransferase domain containing 1). Its specific role in glaucoma biology remains under investigation; current evidence positions it as a signal at a locus associated with ACG risk.

Multi-ancestry discovery across 2,068 traits — a genome-wide association study within the VA Million Veteran Program, one of the largest and most ancestrally diverse biobank studies to date, identified genetic loci including the GLIS3, HERC2, KCNQ5, and PCMTD1 regions as associated with primary angle-closure glaucoma risk across African, European, Hispanic, and Asian ancestry groups.^[1]

What the research says

Research base: Robust.

The genetic architecture of angle-closure glaucoma has been studied across multiple large cohorts, with accumulating evidence from population-based studies in East Asian, European, and multi-ancestry settings. The VA Million Veteran Program study (Verma et al., 2024) contributed a particularly broad multi-ancestry analysis spanning 2,068 traits including primary angle-closure glaucoma, providing replication across diverse genetic backgrounds and strengthening the evidence for the loci described above.^[1]

Prior to large-scale biobank studies, research on ACG genetics largely focused on East Asian populations, where ACG prevalence is highest. The identification of consistent signals in multi-ancestry cohorts supports the generalizability of these loci beyond single ancestry groups — an important finding for a condition that disproportionately affects diverse global populations.

Angle-closure glaucoma accounts for approximately half of all glaucoma-related blindness globally despite representing a smaller fraction of glaucoma cases by prevalence — a disparity driven by the severity of acute attacks and the frequency of late detection in the chronic form. Multi-ancestry genome-wide data now provide a foundation for understanding which individuals carry elevated anatomical risk prior to symptom onset.^[1]

The genetics of ACG are mechanistically distinct from those of primary open-angle glaucoma. POAG features genes involved in trabecular meshwork protein function (such as MYOC); ACG genetics center on anterior segment developmental genes and anatomical determinants of chamber depth and angle width. This biological divergence reinforces that ACG and POAG are separate disease entities warranting different screening approaches.

One caveat: with a single large multi-ancestry study as the authorized source for these specific loci, findings await replication in additional cohorts. The underlying biology connecting GLIS3 and HERC2 to anterior segment anatomy is well-supported by developmental studies; the direct variant-to-ACG pathway continues to be refined as functional work expands.

How angle-closure glaucoma affects you

Angle-closure glaucoma's impact depends substantially on whether the closure is acute or chronic, and how early the anatomical risk is identified.

In the acute form, an angle-closure crisis constitutes an ophthalmic emergency. Intraocular pressure can rise from a normal range of 10-21 mmHg to 40-70 mmHg within hours. At those pressures, optic nerve fibers can be irreversibly damaged within hours to days. Permanent visual field loss, or in severe cases loss of functional vision in the affected eye, can result from a single untreated acute episode. Recognizing the warning signs — sudden eye pain, blurred vision with rainbow halos, frontal headache, and nausea — and seeking immediate care is the critical protective action.

In the chronic form, elevated pressure builds gradually as the angle progressively closes over years. Because central vision is spared until late in the disease course, many people are unaware of the progressive peripheral vision loss occurring. Regular eye examinations with angle assessment can detect narrowing before closure occurs.

Anatomical risk factors that correlate with ACG susceptibility include shorter axial eye length (farsightedness/hyperopia), shallower anterior chamber depth, thicker lens, and plateau iris configuration. These are measurable with modern ophthalmic imaging. Family history is a meaningful risk signal: first-degree relatives of someone with ACG have substantially elevated anatomical risk compared to the general population.

Certain medications can trigger acute angle-closure in individuals with narrow angles by dilating the pupil or altering aqueous dynamics. Drug classes with documented ACG-triggering potential include anticholinergics (some bladder medications, antihistamines), sympathomimetics (decongestants), topiramate (a migraine and seizure medication), and some antidepressants. Awareness of this risk allows people with narrow angles to inform their prescribers before starting these medications.

Working with your angle-closure glaucoma result

A higher genetic score for angle-closure glaucoma risk reflects inherited variants associated with this trait in large population studies. It does not confirm that angle closure is present or will occur. The actionable value of this result lies in directing attention toward the monitoring and prevention strategies that benefit individuals with elevated anatomical or genetic risk.

Steps supported by ophthalmologic guidelines

1. Schedule a comprehensive dilated eye examination with angle assessment. Gonioscopy — the standard clinical procedure in which a mirrored lens is placed on the eye to directly visualize the drainage angle — identifies narrow angles before closure occurs. Anterior segment optical coherence tomography (AS-OCT) provides non-contact angle imaging. Either or both can establish your anatomical baseline.

2. Know the warning signs of acute angle-closure. Sudden severe eye or brow pain, abrupt blurring, halos around lights, nausea, and headache represent a same-day ophthalmic emergency. Calling an eye doctor or going to an emergency department without delay can prevent permanent vision loss.

3. Tell every prescriber about your narrow-angle history or risk. Medications with pupillary dilation effects (anticholinergics, sympathomimetics, topiramate, some antidepressants) can precipitate acute closure in susceptible eyes. A note in your medical record and proactive disclosure at each new prescription reduces this risk.

4. Discuss laser peripheral iridotomy (LPI) with your ophthalmologist. LPI is a brief outpatient laser procedure that creates a small opening in the peripheral iris, allowing aqueous humor to bypass a blocked pupillary pathway and equalizing pressure across the iris. For individuals with confirmed narrow angles, LPI is a preventive option that substantially reduces acute attack risk.

5. If you are farsighted (hyperopic), maintain regular eye exams. Hyperopic eyes tend to have shorter axial lengths and shallower anterior chambers — the same anatomical profile that predisposes to angle closure. This overlap makes regular monitoring particularly relevant.

6. Alert first-degree family members. Because both the genetic predisposition and the underlying anterior segment anatomy are heritable, siblings and children of individuals with narrow angles or ACG carry elevated anatomical risk and benefit from proactive screening.

Related traits and genes

Angle-closure glaucoma shares genetic and biological territory with several traits tracked by ExomeDNA.

The KCNQ5 locus connects angle-closure glaucoma to intraocular pressure — a continuously measured eye pressure trait driven partly by the same aqueous humor secretion and drainage balance that angle-closure disrupts. Individuals with variants affecting IOP regulation may carry compounded risk when anatomical angle-narrowing is also present.

Myopia (nearsightedness) involves longer axial eye length, which is the opposite of the short-axis anatomy that predisposes to angle closure. The inverse anatomical relationship between myopia and ACG risk is well-established: high myopia is protective against ACG, while hyperopia is a risk factor. Understanding your myopia-related variants provides complementary context to your ACG result.

The HERC2 region's role in both eye pigmentation and anterior segment anatomy connects ACG genetics to iris pigment dispersion — a condition in which pigment granules shed from the iris and clog the trabecular meshwork. Though mechanistically different from angle-closure, both involve iris anatomy and IOP elevation as convergent downstream effects.

The developmental role of GLIS3 in multiple organ systems, including the kidney and pancreas, means variants in this region intersect with traits beyond the eye. ExomeDNA covers type 2 diabetes risk and kidney function traits where GLIS3 has been implicated — reviewing those results alongside this ACG result provides a more complete picture of how GLIS3 variation may be acting across your biology.

Frequently asked questions

What is the difference between angle-closure and open-angle glaucoma? Open-angle glaucoma — the most common form — involves a drainage angle that remains physically open but drains fluid too slowly, leading to gradual silent pressure buildup. Angle-closure glaucoma involves the iris physically blocking or narrowing the drainage angle itself. The distinction is anatomical and visible on clinical examination. The two forms have different risk populations, partly different genetics, and different treatment approaches, though both ultimately damage the optic nerve if intraocular pressure is not controlled.

Can angle-closure glaucoma be prevented if I carry these genetic variants? Genetic variants associated with ACG risk do not make angle closure inevitable. They reflect inherited anatomy — primarily anterior chamber geometry — that increases susceptibility. The most effective preventive tools are early identification of narrow angles through gonioscopy or AS-OCT imaging, and consideration of laser peripheral iridotomy (LPI) for confirmed narrow angles. Regular eye examinations allow clinicians to assess angle width and intervene before a closure event occurs.

What are the symptoms of an acute angle-closure attack? An acute attack typically presents as sudden, severe pain in or around one eye, often accompanied by frontal headache, blurred vision, rainbow-colored halos around lights, redness of the eye, and sometimes nausea or vomiting. These symptoms represent a same-day ophthalmic emergency. Elevated intraocular pressure during an acute attack can cause irreversible optic nerve damage within hours, so prompt evaluation is essential.

Why is angle-closure glaucoma more common in East Asian populations? East Asian populations have, on average, shorter axial eye lengths and shallower anterior chambers — anatomical features that predispose to angle narrowing. This anatomical difference is partly genetic and partly reflects population-level variation in eye development. The genetic loci identified in multi-ancestry studies appear to operate across ancestry groups, but the baseline anatomical starting point means that individuals of East Asian ancestry reach the threshold for angle narrowing at a higher rate in population studies.^[1]

Which medications can trigger angle-closure in people with narrow angles? Several drug classes can dilate the pupil or alter aqueous humor dynamics in ways that precipitate acute angle-closure in susceptible individuals. These include anticholinergics (found in some bladder medications, motion-sickness drugs, and antihistamines), sympathomimetics (in nasal decongestants and eye drops), topiramate (used for migraines and seizures), and certain antidepressants including tricyclics and some SSRIs. Anyone with known narrow angles or a family history of ACG should inform their prescribers before starting these medications. Eye drops containing these agents require particular attention.

Does a higher ExomeDNA angle-closure score mean I currently have elevated eye pressure? No. The genetic score reflects inherited variants associated with angle-closure glaucoma in population studies — primarily through their effects on anterior segment anatomy and aqueous dynamics. Actual intraocular pressure is determined by the interaction of these genetic tendencies with age, medications, eye anatomy measured at a clinical examination, and other factors. A genetic score for ACG risk is a prompt to schedule ophthalmic evaluation, not a measurement of current IOP. Only a clinical eye examination can assess current pressure and angle status.

References

1. Verma A, et al. Diversity and scale: Genetic architecture of 2,068 traits in the VA Million Veteran Program. PLOS Genetics. 2024. PMID: 39024449.

Data sources:

• GWAS Catalog (NHGRI-EBI, accessed 2026-05-29)
• Open Targets Platform (CC0 1.0, accessed 2026-05-29)
• ClinVar (NCBI, accessed 2026-05-29) — entries at 2-star review status or above
• ClinGen Gene-Disease Validity (CC0 1.0, accessed 2026-05-29)

ExomeDNA genetic results are for wellness and educational purposes only. Consult a clinician for personalized health guidance.